Impact of nodal status in determining multimodal treatment strategies in non‐cardia gastric cancer

Abstract

AbstractBackgroundPatients with resectable noncardia gastric cancer may be subjected to perioperative chemotherapy (PEC), postoperative chemoradiation (POCR), or postoperative chemotherapy (POC). We analyzed these treatment strategies to determine optimal therapy based on nodal status.MethodThe National Cancer Database was used to identify patients with resected noncardia gastric cancer (2004–2016). Patients were stratified based on clinical nodal status–negative (cLN−), positive (cLN+) and pathological nodal status (pLN−, pLN+). In cLN− patients who underwent upfront resection and were upstaged to pLN+, POC, and POCR were compared. Overall survival (OS) with PEC, POCR, and POC were compared in cLN− and cLN+.ResultsWe identified 6142 patients (cLN−: 3831; cLN+: 2311). In cLN− patients who underwent upfront resection (N = 3423), 69% were upstaged to pLN+ disease (N = 2499; POCR = 1796, POC = 703). On MVA, POCR was associated with significantly improved OS when compared to POC (hazard ratio [HR]: 0.75; p < 0.001).In patients with cLN− disease (PEC = 408; POCR = 2439; POC = 984), PEC(HR: 0.77; p = 0.01) and POCR(HR: 0.81; p < 0.001) were associated with improved OS compared with POC. In cLN+ group (PEC = 452; POCR = 1284; POC = 575), POCR was associated with improved OS compared with POC (HR: 0.81; p < 0.01), and trend towards improved OS was noted when PEC(HR: 0.83; p = 0.055) was compared with POC.ConclusionPostoperative chemoradiation may be the preferred treatment strategy over postoperative chemotherapy in non‐cardia gastric cancer patients who receive upfront resection and are upstaged from clinically node negative to pathologically node positive disease.